Harmony Biosciences Holdings, Inc. (HRMY) Balance Sheet

The shift from accumulated losses to positive retained earnings over roughly nine quarters suggests WAKIX has moved the company from a cash-consuming launch phase into sustained profitability. Equity growth of about $540M over the same period, with minimal dilution, implies that internally generated earnings rather than external capital are now funding balance sheet expansion. Investors should monitor whether this trajectory holds as revenue growth decelerates, since the balance sheet's improvement depends on continued earnings rather than one-time items.

The reduction in D/E largely reflects equity growth outpacing a modest decline in total debt, rather than deliberate deleveraging alone. At these levels, debt service is unlikely to constrain operating flexibility, which supports the company's capacity to fund pipeline expansion. The remaining debt warrants periodic review of its maturity profile and covenant terms, since the source data does not disclose these details.

A current ratio consistently above 3 and cash balances that have grown from $317.3M to $647.1M suggest the company can absorb working capital swings without external financing. The recent dip in cash from $752.5M in 2025Q4 to $549.8M in 2026Q2 shows that liquidity is not static, and quarterly timing of receivables and inventory appears to drive much of that variation. Continued reliance on operating cash generation would be the key assumption to watch.

The steady amortization of goodwill without a reported impairment indicates the intangible balance is being written down on schedule rather than reassessed. Net PP&E reported at effectively zero in recent quarters is consistent with outsourced manufacturing and an asset-light model. The declining intangible base reduces impairment exposure over time, but it also means the balance sheet increasingly reflects liquid assets whose future deployment will determine returns.